Shockwave therapy marketing: cleared vs off-label claims

Shockwave therapy is offered by urology practices, men’s health clinics, orthopedic and sports medicine practices, podiatrists, chiropractors, physical therapists and wound care centers. The same word covers very different devices and very different claims: breaking up kidney stones, treating chronic heel pain, healing wounds, and a long list of uses that clinics advertise without any FDA indication behind them. The question for every page and ad is the same: what has FDA actually cleared or approved this device for, and what are you claiming?

This guide covers the shock wave device types in FDA’s databases, how to describe a device by its own indication, why erectile dysfunction claims are the hardest case, and how result claims, success rates and testimonials fit under the FTC Act. For device wording across specialties, see our guide to medical device marketing claims. Clinics offering shockwave for ED should also read our guide to men’s health clinic marketing, and orthopedic practices our guide to orthopedic practice marketing. Pulsed electromagnetic field devices are covered in our guide to PEMF therapy marketing rules.

This is general information, not legal or medical advice. Sources cited were checked on November 1, 2026: FDA’s Product Classification database entries for product codes NBN, OME, PZL and LNS; FDA premarket approval records for product code NBN and FDA’s device classification data, both through openFDA (data last updated October 19, 2026); 21 CFR 876.5990, 878.4685 and 807.97 and 16 CFR 255.2 in the eCFR version as of October 29, 2026; 21 USC 396 and 15 USC 45, 52 and 55 in the Cornell LII text of the U.S. Code; and the FTC Health Products Compliance Guidance (December 2022). We did not read any device maker’s labeling, the medical literature, Medicare or insurer coverage rules, ad platform policies or any state law on who may operate these devices for this guide.

The short version

“Shockwave” is not one device. FDA’s classification data lists separate shock wave device types for urinary stones, gallbladder stones, intravascular lithotripsy, diabetic foot ulcers, pain relief and atrophic nonunion fractures, each with its own class and pathway.
Claims follow the device’s own indication. The pain relief approvals we read are for chronic plantar fasciitis (heel pain) and chronic lateral epicondylitis (tennis elbow) in adults whose symptoms lasted months and did not respond to conservative treatment. They are not a general license for “pain”, “sports injuries” or “joint repair”.
No device type names erectile dysfunction. Our search of FDA’s classification data on November 1, 2026 found no shock wave device type for ED. A clinician may use a legally marketed device off-label, but 21 USC 396 says that does not change “any existing prohibition on the promotion of unapproved uses.”
“Approved” and “cleared” mean different things. Pain relief and nonunion fracture devices are Class III devices on the premarket approval (PMA) pathway. Wound and stone devices are Class II and reach the market through 510(k), and 21 CFR 807.97 says a clearance does not denote official approval.
No borrowed success rates. A cure rate from a study of a different device, condition or protocol does not substantiate your ad (15 USC 52, 55; FTC Health Products Compliance Guidance).

What FDA has classified and approved

When we searched FDA’s device classification data on November 1, 2026 for device names containing “shock wave” or “shockwave”, it returned six device types. The four relevant to outpatient clinics:

Extracorporeal shock wave lithotripter (product code LNS, 21 CFR 876.5990). A Class II device that “focuses ultrasonic shock waves into the body to noninvasively fragment urinary calculi within the kidney or ureter.” It reaches the market through 510(k).
Extracorporeal shock wave device for treatment of chronic wounds (product code PZL, 21 CFR 878.4685). A Class II “prescription device that focuses acoustic shock waves onto the dermal tissue,” with special controls that include physician labeling on the typical course of treatment. FDA’s classification data names the product code for diabetic foot ulcers. It reaches the market through 510(k).
Generator, shock-wave, for pain relief (product code NBN). A Class III device reviewed by FDA’s orthopedic devices office through premarket approval. The original approval orders we read, dated from October 2000 to January 2016, are for chronic proximal plantar fasciitis, and one for chronic lateral epicondylitis. They describe patients with symptoms for six months or more and a history of unsuccessful conservative therapy, and several name patients 18 years or older.
Extracorporeal shock wave treatment (product code OME). A Class III device on the PMA pathway, defined in FDA’s classification database “for use for extracorporeal shock wave treatment of atrophic nonunion fractures.” Our search of FDA’s PMA data returned no approval records under this code.

The other two types, for gallbladder stones and intravascular lithotripsy inside blood vessels, are hospital devices and outside the scope of this guide. None of the six device types names erectile dysfunction, sexual function, cellulite, tendon repair in general or “regeneration”.

For your own device, the authoritative description is its own submission: the 510(k) number or PMA number, and the indications for use in it. Ask the manufacturer or distributor for that number before you write a line about the device, then look it up in FDA’s databases yourself.

Describe your device by its own indication

Shockwave marketing goes wrong when one approved or cleared use is stretched to cover a menu. The approval orders for pain relief generators are specific about the condition (chronic plantar fasciitis or chronic lateral epicondylitis), the patient (adults, in several orders) and the history (symptoms for six months or more and failed conservative treatment). A page that says “FDA-approved shockwave for pain” or “FDA-approved for sports injuries” claims much more than that.

Name the condition, not a body system. “Shockwave treatment for chronic heel pain from plantar fasciitis” can match an approved indication. “Shockwave for joint pain, back pain and arthritis” does not.
Include the conditions of the indication. If your device is approved for patients whose symptoms lasted six months and did not respond to other treatment, say that the treatment is for people in that situation, not a first step for a new injury.
“FDA-approved” only for a PMA device and only for its approved indication. For a 510(k) device, 21 CFR 807.97 says any representation that creates an impression of official approval because of a clearance “is misleading and constitutes misbranding.” Say “FDA-cleared” for a cleared device’s cleared use.
Check that your unit is the device type you think it is. A unit sold as shockwave or “acoustic wave” therapy is not necessarily one of the device types above. If your unit’s submission is under a different device type, its claims are limited to that type.

Erectile dysfunction: the hardest claim to make

Ads for shockwave ED treatment can use phrases like “FDA-approved”, “restores natural function” or “no more pills”. None of the shock wave device types we found in FDA’s classification data names erectile dysfunction. That leaves two separate questions.

The first is whether a clinician may use the device for ED at all. 21 USC 396 says nothing in the Federal Food, Drug, and Cosmetic Act limits “the authority of a health care practitioner to prescribe or administer any legally marketed device to a patient for any condition or disease within a legitimate health care practitioner-patient relationship.” That is a question of medical judgment and state practice rules, which we do not address.

The second is how the use may be promoted, and the same section answers part of it: it “shall not change any existing prohibition on the promotion of unapproved uses of legally marketed devices.” Separately, the FTC Act makes it unlawful to disseminate a false advertisement to induce the purchase of devices or services (15 USC 52) and declares deceptive acts or practices unlawful (15 USC 45(a)(1)). The FTC Health Products Compliance Guidance says health benefit claims require competent and reliable scientific evidence, which it says generally means randomized, controlled human clinical testing.

In practice, a clinic that offers shockwave for ED should not call it FDA-approved or FDA-cleared for ED, should not promise restored function, a cure or the end of medication, and should not describe it as a proven alternative to other treatments. If you advertise the service at all, describe it as an evaluation and a treatment option your clinicians discuss, say plainly that the device is not FDA-cleared or approved for ED once you have confirmed that from its indications, and have a health care attorney review the page. Our men’s health clinic marketing guide covers the rest of an ED service page.

Wound care and stone clinics

Wound care centers using a device under 21 CFR 878.4685 have a cleared device type, but it is a prescription device and Class II. Say “FDA-cleared” for the wound type in your device’s indication, not “FDA-approved”, and do not extend it to wound types or skin conditions outside that indication. Healing claims, such as a percentage of wounds closed or a number of weeks to closure, need evidence for your device and protocol. Our guide to wound care marketing ideas covers the rest of a wound program’s marketing.

Lithotripsy for kidney and ureteral stones is a clearly defined use. The urology and kidney stone guides cover how to describe it in neutral terms and without stone-free or painless promises; see kidney stone clinic marketing.

Results, success rates and testimonials

An advertisement is false under the FTC Act if it is “misleading in a material respect,” which includes failing to reveal facts material in light of what the ad says (15 USC 55(a)(1)). For shockwave, these claims need attention:

Success or cure rates. “90% success rate” or “works for 8 in 10 patients” is a specific claim. You need evidence for that figure, for that condition, device and protocol. The FTC guidance says research on a different formulation may not support your product, and the same reasoning applies to a different device, energy setting or treatment schedule. If you have no such evidence, describe the treatment without a number.
“Regenerates”, “repairs” or “heals”. These are health benefit claims that go beyond pain relief. They need competent and reliable scientific evidence for the condition you name.
Session counts. “Results in 3 sessions” is a result claim. “A typical course at our clinic is 3 sessions, and plans vary” describes your protocol.
“No side effects” or “risk-free”. Leaving out risks can be a failure to reveal material facts (15 USC 55(a)(1)). Describe risks in the words your clinicians approve and the device labeling uses.

Under 16 CFR 255.2(a), an ad using consumer endorsements is read as representing that the product is effective for the purpose shown, and the advertiser needs substantiation as if it had made the claim directly. Under 16 CFR 255.2(b), an endorsement about a central attribute is likely to be read as representative of what consumers generally achieve, unless the ad clearly and conspicuously discloses the generally expected performance. A patient video saying shockwave cured their ED is your ED claim. Ask for reviews about the visit and the care instead. See our guide to patient testimonials and before-and-after photos.

An example (made up)

This illustration is invented to show how the rules fit together. A sports medicine clinic’s landing page reads: “FDA-approved shockwave therapy. Heals tendons, joints and ED naturally. 91% success rate. No side effects, results in 3 sessions.” The clinic’s unit is a pain relief generator approved through PMA for chronic proximal plantar fasciitis.

Fixes: the headline becomes “Shockwave treatment for chronic heel pain from plantar fasciitis”, and the page says the device is FDA-approved for adults with heel pain from chronic plantar fasciitis who have had symptoms for six months or more and did not improve with other treatment, matching the approval order. “Tendons, joints” goes, because the approval covers one condition. “ED” goes from this page; the clinic’s men’s health page now says the device is not FDA-cleared or approved for ED, which the clinic confirmed from its indications. The 91% figure goes, because it came from a study of another device. “No side effects” and “results in 3 sessions” are replaced with a short risks section and “a typical course at our clinic is three sessions; plans vary.”

Checklist

You have your device’s 510(k) or PMA number and have read its indications for use in FDA’s database.
Each page names the condition in the indication, including patient and history conditions, not a body system or “pain” in general.
“FDA-approved” only for a PMA device’s approved indication; “FDA-cleared” for a 510(k) device’s cleared use (21 CFR 807.97).
No claim that any shock wave device is FDA-cleared or approved for erectile dysfunction; no cure, restored function or “no more pills” promises (21 USC 396, 15 USC 45, 52).
No success or cure rates without evidence for your condition, device and protocol (15 USC 52, 55; FTC guidance).
No “regenerates”, “repairs” or “heals” claims without competent and reliable scientific evidence for the condition named.
Risks described; no “no side effects” or “risk-free”.
Testimonials limited to the visit and care, with typical results disclosed where a result is shown (16 CFR 255.2).
Who operates the device checked against your own state’s rules.

How we help

We build service pages and campaigns for urology, men’s health, orthopedic, sports medicine, podiatry and wound care practices, with device and result claims checked against the sources above: website design, healthcare SEO for condition and treatment searches, and lead generation campaigns. We do not give legal opinions on device status or off-label use, and we are not a law firm.

Is shockwave therapy FDA-approved?

Some shock wave devices are, for specific uses. FDA’s pain relief generator approvals we read are for chronic plantar fasciitis and chronic lateral epicondylitis in patients who did not respond to conservative treatment. Lithotripters and chronic wound devices are Class II devices cleared through 510(k), not approved. Check your own device’s PMA or 510(k) number and its indications.

Can we advertise shockwave therapy for erectile dysfunction?

No shock wave device type in FDA’s classification data names erectile dysfunction as of our November 1, 2026 search. 21 USC 396 lets practitioners use legally marketed devices off-label but does not change any prohibition on promoting unapproved uses, and any health claim needs competent and reliable scientific evidence under the FTC Act. Never call it FDA-approved or cleared for ED, and have an attorney review any ED page.

Can we say shockwave works for back pain or arthritis?

Not on the strength of the pain relief approvals we read, which name chronic plantar fasciitis and chronic lateral epicondylitis. A claim for another condition is a claim FDA has not reviewed for that device, and it needs its own evidence under 15 USC 52 and 55.

Can we publish a success rate?

Only with evidence for that figure, for the same condition, device and protocol you use. The FTC says research on a different formulation may not support a product; a study of a different device or schedule raises the same problem. Without that evidence, describe the treatment without a number.

Can we call our wound shockwave device FDA-approved?

No. A device under 21 CFR 878.4685 is a Class II prescription device that reaches the market through 510(k), and 21 CFR 807.97 says a clearance does not denote official approval. Say FDA-cleared for the wound type in your device’s indications.

Sources

More in Cash-pay, aesthetic and wellness care

Shockwave therapy marketing rules: cleared uses vs off-label claims